Mister Spex Valuation
Is MRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MRX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRX?
Key metric: As MRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MRX's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | €226.27m |
| Market Cap | €51.45m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | -1.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MRX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
BIKE Bike24 Holding | 0.2x | 6.5% | €53.0m |
ART Artnet | 1.8x | n/a | €38.8m |
WFA Weng Fine Art | 3.5x | n/a | €21.2m |
DOU Douglas | 0.4x | 6.2% | €2.0b |
MRX Mister Spex | 0.2x | 2.6% | €51.5m |
Price-To-Sales vs Peers: MRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.5x).
Price to Sales Ratio vs Industry
How does MRX's PS Ratio compare vs other companies in the DE Specialty Retail Industry?
Price-To-Sales vs Industry: MRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Specialty Retail industry average (0.4x).
Price to Sales Ratio vs Fair Ratio
What is MRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 0.08x |
Price-To-Sales vs Fair Ratio: MRX is expensive based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.56 | €5.21 +234.1% | 40.4% | €7.00 | €1.85 | n/a | 4 |
| Nov ’25 | €2.00 | €5.63 +182.0% | 34.6% | €7.00 | €2.30 | n/a | 4 |
| Oct ’25 | €2.25 | €5.70 +153.3% | 30.7% | €7.00 | €2.30 | n/a | 5 |
| Sep ’25 | €2.34 | €5.70 +143.6% | 30.7% | €7.00 | €2.30 | n/a | 5 |
| Aug ’25 | €2.76 | €6.30 +128.3% | 30.8% | €9.00 | €3.00 | n/a | 5 |
| Jul ’25 | €2.84 | €6.30 +121.8% | 30.8% | €9.00 | €3.00 | n/a | 5 |
| Jun ’25 | €3.19 | €6.26 +96.2% | 32.1% | €9.00 | €2.80 | n/a | 5 |
| May ’25 | €2.90 | €7.00 +141.4% | 29.4% | €9.00 | €3.40 | n/a | 5 |
| Apr ’25 | €3.30 | €7.08 +114.4% | 30.4% | €10.00 | €3.35 | n/a | 6 |
| Mar ’25 | €4.02 | €7.22 +79.7% | 29.0% | €10.00 | €3.50 | n/a | 6 |
| Feb ’25 | €3.37 | €6.73 +100.0% | 33.9% | €10.00 | €3.50 | n/a | 7 |
| Jan ’25 | €3.27 | €6.74 +106.5% | 33.7% | €10.00 | €3.20 | n/a | 7 |
| Dec ’24 | €2.77 | €6.74 +143.9% | 33.7% | €10.00 | €3.20 | n/a | 7 |
| Nov ’24 | €2.76 | €6.86 +148.9% | 37.0% | €11.00 | €3.00 | €2.00 | 7 |
| Oct ’24 | €3.32 | €7.00 +110.8% | 33.4% | €11.00 | €4.00 | €2.25 | 7 |
| Sep ’24 | €3.90 | €7.00 +79.7% | 33.4% | €11.00 | €4.00 | €2.34 | 7 |
| Aug ’24 | €3.99 | €7.09 +77.8% | 31.5% | €11.00 | €4.20 | €2.76 | 7 |
| Jul ’24 | €3.19 | €7.09 +122.5% | 31.5% | €11.00 | €4.20 | €2.84 | 7 |
| Jun ’24 | €3.72 | €6.88 +85.3% | 37.8% | €11.00 | €3.60 | €3.19 | 6 |
| May ’24 | €3.80 | €8.02 +111.0% | 48.2% | €15.00 | €4.20 | €2.90 | 6 |
| Apr ’24 | €4.02 | €8.32 +106.9% | 45.7% | €15.00 | €4.00 | €3.30 | 6 |
| Mar ’24 | €4.01 | €8.43 +110.3% | 43.7% | €15.00 | €4.00 | €4.02 | 6 |
| Feb ’24 | €3.91 | €8.43 +116.0% | 43.7% | €15.00 | €4.00 | €3.37 | 6 |
| Jan ’24 | €3.96 | €8.35 +111.1% | 46.7% | €15.00 | €4.00 | €3.27 | 6 |
| Dec ’23 | €4.29 | €8.60 +100.7% | 44.4% | €15.00 | €4.00 | €2.77 | 6 |
| Nov ’23 | €3.13 | €8.55 +173.2% | 51.3% | €15.00 | €4.00 | €2.76 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Inchcape
UK£3.0b
Operates as an automotive distributor and retailer.
IJCA
UK£9.01
7D
0.3%
1Y
20.1%
Best Buy
US$18.6b
Engages in the retail of technology products in the United States, Canada, and international.
BUY
US$82.02
7D
-6.3%
1Y
31.2%
Luk Fook Holdings (International)
HK$8.8b
An investment holding company, engages in sourcing, designing, wholesaling, trademark licensing, and retailing various gold and platinum jewelry, and gem-set jewelry products.
LUY1
HK$1.77
7D
1.7%
1Y
-25.0%